|
Cerebrovascular accident
|
0.210 |
Biomarker
|
group |
RGD |
Double immunohistochemistry analysis revealed that stroke substantially increased the number of NG2+OPCs with nuclear HDAC1 and HDAC2 immunoreactivity and cytoplasmic HDAC4 which were associated with augmentation of proliferating OPCs, as determined by BrdU and Ki67 double reactive cells after stroke.
|
24657831 |
2014 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
|
19553350 |
2009 |
|
Fetal Growth Retardation
|
0.200 |
Biomarker
|
phenotype |
RGD |
Prenatal caffeine ingestion induces aberrant DNA methylation and histone acetylation of steroidogenic factor 1 and inhibits fetal adrenal steroidogenesis.
|
24717552 |
2014 |
|
Fetal Growth Retardation
|
0.200 |
Biomarker
|
phenotype |
RGD |
Uteroplacental insufficiency affects epigenetic determinants of chromatin structure in brains of neonatal and juvenile IUGR rats.
|
16380407 |
2006 |
|
Fetal Growth Retardation
|
0.200 |
Biomarker
|
phenotype |
RGD |
The fetal IUGR state was characterized by loss of USF-1 binding at the proximal promoter of Pdx1, recruitment of the histone deacetylase 1 (HDAC1) and the corepressor Sin3A, and deacetylation of histones H3 and H4.
|
18464933 |
2008 |
|
Pulmonary Hypertension
|
0.200 |
Biomarker
|
phenotype |
RGD |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Right Ventricular Hypertrophy
|
0.200 |
Biomarker
|
disease |
RGD |
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
22711276 |
2012 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
PSYGENET |
Postmortem brain studies have shown that HDAC1-a lysine deacetylase with broad activity against histones and nonhistone proteins-is frequently expressed at increased levels in prefrontal cortex (PFC) of subjects diagnosed with schizophrenia and related disease.
|
23664640 |
2013 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
PSYGENET |
The mRNA expression level of an epigenetically regulated schizophrenia candidate gene GAD67 was strongly and negatively correlated with the mRNA expression levels of HDAC1, HDAC3 and HDAC4 levels.
|
17961987 |
2008 |
|
Mood Disorders
|
0.300 |
Biomarker
|
group |
PSYGENET |
These results provide evidence that selective inhibition of HDAC1 and HDAC2 in brain may provide an epigenetic-based target for developing improved treatments for mood disorders and other brain disorders with altered chromatin-mediated neuroplasticity.
|
23967191 |
2013 |
|
Schizophrenia
|
0.360 |
AlteredExpression
|
disease |
LHGDN |
The mRNA expression level of an epigenetically regulated schizophrenia candidate gene GAD67 was strongly and negatively correlated with the mRNA expression levels of HDAC1, HDAC3 and HDAC4 levels.
|
17961987 |
2008 |
|
Squamous cell carcinoma
|
0.320 |
AlteredExpression
|
disease |
LHGDN |
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
|
12579268 |
2003 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
High HDAC1 expression might have an important role in the aggressiveness and cell dedifferentiation, and its expression status may be a useful biomarker for predicting the outcome of the patients with HCC.
|
18004079 |
2007 |
|
Glioma
|
0.040 |
Biomarker
|
disease |
LHGDN |
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
|
18708058 |
2008 |
|
Lymphoma, T-Cell, Cutaneous
|
0.040 |
AlteredExpression
|
disease |
LHGDN |
The immunohistochemical expression of HDAC1, HDAC2, HDAC6, and acetylated H4 was examined in 73 CTCLs and the results related to histological subtypes and overall survival.
|
18671804 |
2008 |
|
Colorectal Neoplasms
|
0.030 |
Biomarker
|
group |
LHGDN |
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
|
18347167 |
2008 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
LHGDN |
Melanoma senescence: HDAC1 in focus.
|
17850504 |
2007 |
|
Mammary Neoplasms
|
0.030 |
Biomarker
|
group |
LHGDN |
Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells.
|
15155736 |
2004 |
|
Mammary Neoplasms
|
0.030 |
AlteredExpression
|
group |
LHGDN |
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
|
16172792 |
2005 |
|
Prostatic Neoplasms
|
0.020 |
Biomarker
|
group |
LHGDN |
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
|
16914734 |
2006 |
|
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.
|
15042618 |
2004 |
|
Stomach Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Expression profile of histone deacetylase 1 in gastric cancer tissues.
|
11749695 |
2001 |
|
Stomach Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers.
|
12087472 |
2002 |
|
Anoxia
|
0.010 |
Biomarker
|
phenotype |
LHGDN |
Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors.
|
17935135 |
2008 |
|
Endometrial Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
|
18714364 |
2008 |